TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Most recent LVEF to be ≤ 40% by any method within 12 months of randomization.~* High risk heart failure as defined by the following criteria:~A Heart Failure Event in the prior 12 months, defined as any one of the following:~* HF Hospitalization~* Treatment in the Emergency Department (or equivalent) for Heart Failure~* Outpatient treatment for heart failure with intravenous diuretics~AND~* NT-proBNP greater than 2000 pg/mL or BNP greater than 400 pg/mL at any time during the 30 days prior to randomization~* Willing to provide informed consent~Exclusion Criteria:~* Acute coronary syndrome (clinical diagnosis) or cardiac revascularization procedure within 30 days~* Cardiac resynchronization therapy (CRT) within prior 3 months or current plan to implant CRT device~* Active myocarditis, Hypertrophic obstructive cardiomyopathy, pericarditis, or restrictive cardiomyopathy~* Severe stenotic valvular disease~* Anticipated heart transplantation or ventricular assist device within 12 months~* Chronic inotropic therapy~* Complex congenital heart disease~* End stage renal disease with renal replacement therapy~* Non cardiac terminal illness with expected survival less than 12 months~* Women who are pregnant or planning to become pregnant~* Inability to comply with planned study procedures~* Enrollment or planned enrollment in another clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual Care (Type: EXPERIMENTAL): Usual Care group will receive standard heart failure treatment based on the doctor's best judgment and following the recommendation of current guidelines. This will typically include the use of medicines such as beta-blockers, ACE-inhibitors, and diuretics, all of which are approved, recommended treatments for heart failure.
- Biomarker-Guided Care (Type: EXPERIMENTAL): Device: Biomarker-Guided care NT-proBNP The Biomarker Guided Therapy group will receive the standard heart failure treatments. In addition, the doctor will use the results of a blood test called NT-proBNP to help adjust the treatments and drug doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Serotonin/Dopamine Antagonism of Cocaine Effect: 1 - 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Please contact site for information.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Insulin Treatment in Diabetic Older People With Heart Failure.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. men and women aged ≥70 years;~2. at discharge after admission to hospital for worsening of HF or ambulatory patients with chronic HF;~3. New York Heart Association (NYHA) class II or III~4. with any level of left ventricular ejection fraction;~5. plasma natriuretic peptide (BNP) ≥200 pg/mL or N-terminal pro-BNP ≥900 pg/mL (NT pro-BNP)~6. prior history or newly diagnosed T2DM;~7. candidate by the responsible physician to insulin therapy;~8. signed informed consent.~Exclusion Criteria:~1. significant renal insufficiency (GFR \<30 mL/min/1.73 m2) or severe liver disease (liver function test abnormalities (alanine or aspartate aminotransferase ≥ 3 × upper limit of normal \[ULN\]);~2. levels of hemoglobin \<10 g/dl;~3. HbA1c ≤5% or ≥11%;~4. unstable diabetes: type of diabetes presentation in patients with an anamnesis of frequent episodes of hypoglycemia, hyperglycemic hyperosmolar state, ketoacidosis or lactic acidosis;~5. planned CV surgery or angioplasty in 3 months;~6. any non-cardiac disease that shortens life expectancy to\<1 year (e.g.most cancers);~7. inability to comply with study protocol;~8. participation to another interventional clinical study.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- non insulin (Type: NO_INTERVENTION): standard care + antidiabetic therapy non insulin
- Insulin (Type: EXPERIMENTAL): standard care including insulin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of a Supplement Enriched in Hydroxymethylbutyrate and Vitamin D on Muscle Strength in Hip Fracture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over 65 years of age after hip fracture surgery.~* Ability to walk before fracture.~Exclusion Criteria:~* Chronic renal failure, defined as a glomerular filtration rate less than 60 mL/min/1.73 m2, or serum creatinine of 0.9 mg/dL in women or 1.2 mg/dL in men.~* Following a diet with protein restriction.~* Need for enteral or parenteral nutrition.~* Need for medication with orexigenic or anabolic effect, or long-term corticosteroids.~* Active neoplastic disease.~* Cognitive impairment or major psychiatric disorder.~* Lack of signed informed consent.~* Any patient with inability to comply with treatment or not appropriate according to the investigator.

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supplement with HMB and vitamin D (Type: EXPERIMENTAL): Oral administration of 440 mL (2 bottles) of nutritional supplement with HMB and vitamin D each day during 8 weeks.
- Standard nutritional supplement (Type: ACTIVE_COMPARATOR): Oral administration of 440 mL (2 bottles) of standard nutritional supplement each day during 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Compare the Effectiveness Between Existing Treatment and New Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 5 years~* Symptomatic of malaria infection, i.e. history of fever or presence of fever \>37.5°c.~* microscopically confirmed asexual stages of Plasmodium falciparum ≥ 5/500 wbc (may be mixed with non- P.falciparum species) .~* Written informed consent given to participate in the trial.~* Participant or parent/guardian is willing and able to give informed consent for participation in the study.~* Participant or guardian is able to understand and participant can complete the study requirements~Exclusion Criteria:~* Pregnancy or lactation (urine test for β HCG to be performed on any woman of child bearing age unless menstruating).~* P.falciparum asexual stage parasitaemia greater than or equal to 4% red blood cells (175 000/µL).~* Signs or symptoms indicative of severe malaria:~  * Impaired consciousness~ * Severe anaemia (Hct\<15%)~ * Bleeding disorder -evidenced by epistaxis, bleeding gums, frank haematuria, bleeding from venepuncture sites.~ * Respiratory distress~ * Severe jaundice~* Patients who received any P. falciparum treatment within 2 months~* Known hypersensitivity to artemisinins - defined as history of erythroderma/ other severe cutaneous reaction, angioedema or anaphylaxis.~* History of epilepsy and other neurological disorders~* Splenectomy

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DP (Type: EXPERIMENTAL): 2.4 mg/kg dihydroartemisinin AND 20 mg/kg piperaquine once daily on Days 0, 1 and 2
- MAS3 (Type: ACTIVE_COMPARATOR): 4mg/kg artesunate AND 8 mg/kg mefloquine once daily on Days 0, 1 and 2

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Aggressive Pain Management is Associated With Improved Outcomes in Blunt Thoracic Trauma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* \> 18 years of age~* Patients admitted to SFGH trauma service with blunt thoracic trauma (i.e. rib fractures, sternal fractures) requiring IV opioids for pain relief.~Exclusion Criteria:~* Acute spine fractures or pre-existing spine deformity~* Traumatic brain injury or spinal cord injury or altered mental status~* Unstable pelvic fracture or open abdomen~* Hemodynamic instability or major aortic injury (dissection, pseudoaneurysm)~* Coagulopathy~* Mechanical intubation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Trauma patients eligible to receive thoracic epidural (Type: None): Patients admitted to the hospital suffering from blunt thoracic injury and who meet inclusion/exclusion criteria and receive thoracic epidural for pain
- Control Arm (Type: None): Trauma patients eligible to receive thoracic epidural but did not receive thoracic epidural for pain

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assisted Device for Freezing in Parkinson Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* troublesome freezing~Exclusion Criteria:~* dementia

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Detection of freezing (Type: EXPERIMENTAL): freezing parkinsonian patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Diagnosed with cGVHD according to NIH criteria~* Active cGVHD despite treatment with corticosteroids AND one additional immunosuppressive agent for at least 4 weeks, within 52 weeks of enrollment.~* Subject is a recipient of related or unrelated BMT or PBSCT~* Subject underwent transplantation at least 6 months prior to enrollment~* Subject is on stable immunosuppressive regimen for 2 weeks prior to enrollment. Adjustment of immunosuppressive medications to maintain a therapeutic level is permitted.~* Female of child bearing potential must have a negative pregnancy test prior to first dose of alefacept and must agree to practice effective contraception during the study. Men must also agree to use adequate contraception prior to study entry and for the duration of the study.~* Meets medication restriction requirements and agrees to follow medications restrictions during study.~Exclusion Criteria:~* Received donor lymphocyte infusions in the preceding 100 days~* Currently undergoing ECP~* Subject is recipient of related or unrelated UCB~* Subject has bronchiolitis obliterans, bronchiolitis obliterans with organizing pneumonia or cryptogenic organizing pneumonia as the sole manifestation of cGVHD~* Uncontrolled intercurrent active infection.~* Absolute neutrophil count \< 1000/L~* AST, ALT or total bilirubin \> 2x institutional upper limit of normal unless this is a manifestation of GVHD~* Recurrent or progressive malignancy at any time after HCT, as applicable for the individual malignancy~* Subject was in any clinical study within the last 30 days~* Receipt of 5 or more prior agents to treat cGVHD~* Known hypersensitivity to alefacept or any components of the study medication~* Known to be positive for human immunodeficiency virus (HIV) antibodies~* Currently enrolled in any other study for chronic GVHD treatment and receiving treatment under the study or previous participation in this study.~* Pregnant or nursing~* Concurrent illness which, in the opinion of the Investigator, may interfere with treatment or evaluation of safety

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alefacept (Type: EXPERIMENTAL): Alefacept iv

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: OPTIMIZE IDE for the Treatment of ACS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is an eligible candidate for percutaneous coronary intervention (PCI);~* Subject has symptomatic coronary artery disease with objective evidence of ischemia or silent ischemia;~* Subject is an acceptable candidate for coronary artery bypass grafting (CABG);~* Subject has up to 3 de novo target lesions in up to 2 native coronary artery vessels, with no more than 2 lesions in a single vessel, each meeting the angiographic criteria and none of the exclusion criteria.~* Target lesion(s) must be located in a native coronary artery with a visually estimated reference vessel diameter (RVD) ≥ 2.25 mm and ≤ 4.00 mm;~Exclusion Criteria:~* The subject has cardiogenic shock, hemodynamic instability requiring inotropic or mechanical circulatory support, intractable ventricular arrhythmias, or ongoing intractable angina;~* The subject's target lesion(s) is located in the left main artery;~* The subject's target lesion(s) is located within 3 mm of the origin of the left anterior descending (LAD) coronary artery or left circumflex (LCX) coronary artery by visual estimate;~* The subject's target lesion(s) is located within a saphenous vein graft or arterial graft;~* The subject's target lesion(s) will be accessed via a saphenous vein graft or arterial graft;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Svelte (Type: EXPERIMENTAL): None
- Control (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound for Confirmation of Gastric Tube Placement in Critically Ill Patients Under Invasive Mechanical Ventilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical indication of nasogastric tube placement~* Age than 20 years old.~Exclusion criteria:~* Facial trauma or head-base fractures~* Esophageal or gastric resection~* Esophageal strictures or alkaline injury~* Open wound in the area to prevent ultrasonography

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ultrasonography (US) (Type: EXPERIMENTAL): None
- Standard routine (SR) (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Lower Extremity Ankle Foot Orthoses in Parkinson's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of Parkinson's Disease~* Between the ages of 50 and 75~* Ability to walk 150 feet independently over level surfaces with or without an assistive device~* Stable medication usage for the duration of the study (10 weeks)~* Obvious gait dysfunction (Observational Gait Analysis)~* Score of greater than 22 on the Short Orientation-Memory-Concentration Test~Exclusion Criteria:~* Body mass index of greater than 35~* Dorsiflexion range of motion less than neutral (90 degrees)~* Any other uncontrolled health condition for which gait training is contraindicated

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ankle foot orthosis fitting (Type: OTHER): All participants will receive ankle foot orthosis or orthoses. Outcomes will be compared to pre-bracing findings.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Sickle cell disease patients with HbSS~* eGFR \<90 ml/min/1.73m2 (determined by abbreviated 4 variable modification MDRD equation) and/or measured urinary albumin to creatinine ratio \>30mg/g.~* Age ≥18 years~Exclusion Criteria:~* Previous chronic treatment with alkali (including sodium bicarbonate, calcium carbonate or baking soda)~* Bicarbonate level \>25 mEq/L~* Decompensated heart failure~* Uncontrolled systolic blood pressure \>140 mm/Hg (the cutoff for systolic hypertension in SCD is lower than in non-SCD)~* Moderate-to-severe lower extremity edema~* Projected progression to ESRD within 6 months~* Kidney transplantation~* Treatment with immunosuppressives within the last 3 months~* Vasoocclusive (VOC) within 1 week of study entry~* Active (open) leg ulcer~* Change in hydroxyurea dose within the last 3 months, unless a self-limited interruption of a stable dose~* Blood transfusion within 8 weeks, unless on chronic transfusions~* Pregnancy~* Inability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Sodium Bicarbonate (Type: EXPERIMENTAL): Patients will be monitored at baseline bi-weekly intervals for 12 weeks, the first 4 weeks to establish a stable baseline, followed by 8 weeks of alkali therapy, as follows:

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Investigational Use of Erenumab for the Treatment of Fibromyalgia Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~diagnosis of fibromyalgia made by a practicing physician between the ages of 18-85 existing pain for more than 3 months pain resistant to common analgesics or intolerance to common analgesics Active Duty service members widespread pain in at least 7 of 19 areas; as reported by the patient symptom severity scale score over five including symptoms of fatigue, awaking unrefreshed and brain fog~Exclusion Criteria:~Pregnancy ages under 18 and over 85 years of age Non Active Duty service members Anaphylactic reactions Allergy to latex Drug or alcohol abuse severe depression change in CNS active medications in the preceding 2 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): 1ml 0.9% of saline once a month in addition to the standard of care practiced at NMCP.
- Erenumab (Type: EXPERIMENTAL): 140mg (1 ml) of Erenumab injected once a month in addition to the standard of care practiced at NMCP.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Low Dose IV Dexamethasone in Prolonging Caudal Anesthesia in Children Undergoing Genitourinary Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 2 to 10 years~* Scheduled for elective inpatient genitourinary surgical procedure~* Caudal anesthesia standard of care for surgical procedure~* have provided parental consent and assent in accordance with the institutional review board requirements~Exclusion Criteria:~* Abnormal/difficult anatomy~* known allergy to ropivacaine or dexamethasone~* history of documented chronic pain~* existing infection at site of intended injection

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 Ropivacaine (Type: SHAM_COMPARATOR): Group 1 Ropivacaine Intervention: Each patient will receive a caudal with 1ml/kg of 0.2% ropivacaine
- Group 2 Ropivacaine and Dexamethasone (Type: ACTIVE_COMPARATOR): Group 2 Ropivacaine/dexamethasone Intervention: Each patient will receive a caudal with 1ml/kg of 0.2% ropivacaine and 0.1mg/kg of intravenous dexamethasone immediately after caudal placement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues